🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: Lipid-Modifying Therapy (LMT)

Found 23 matching trials

Efficacy and Safety of Alirocumab in Patients With Hypercholesterolemia Not Adequately Controlled With Non-statin Lipid Modifying Therapy or the Lowest Strength of Statin

PHASE3

Primary Objective: To demonstrate the reduction of low-density lipoprotein...

Status

Completed

Location

Investigational Site Number 392028

Start Date

2015-11-30

Trial ID

NCT02584504

Treatments Being Tested

Alirocumab Placebo Atorvastatin Non-statin Lipid-Modifying Therapy Diet Alone

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)

PHASE3

Alirocumab (SAR236553/REGN727) is a fully human monoclonal antibody that bi...

Status

Completed

Location

Investigational Site Number 840857

Start Date

2012-07

Trial ID

NCT01644175

Treatments Being Tested

Placebo (for alirocumab)Alirocumab Lipid-Modifying Therapy (LMT)

Safety, Tolerability, and Effect of Alirocumab in High Cardiovascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies (ODYSSEY APPRISE)

PHASE3

Primary Objective: To provide participants with severe hypercholesterolemi...

Status

Completed

Location

Investigational Site Number 040001

Start Date

2015-06-23

Trial ID

NCT02476006

Treatments Being Tested

ALIROCUMAB SAR236553 (REGN727)placebo (for injection training only)ezetimibe atorvastatin rosuvastatin simvastatin

Evaluation of Alirocumab in Addition to Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia in South Korea and Taiwan

PHASE3

Primary Objective: To demonstrate the reduction of low-density lipoprotein...

Status

Completed

Location

Investigational Site Number 410001

Start Date

2015-01

Trial ID

NCT02289963

Treatments Being Tested

Placebo (for Alirocumab)Alirocumab Lipid-Modifying Therapy (LMT)

Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I)

PHASE3

This is a randomized, double-blind, active-comparator, parallel-group study...

Status

Completed

Location

Multiple Locations

Start Date

2012-10

Trial ID

NCT01730040

Treatments Being Tested

Alirocumab Atorvastatin Ezetimibe Rosuvastatin Placebo

Study of Alirocumab (REGN727/SAR236553) added-on to Rosuvastatin Versus Other Lipid Modifying Treatments (LMT) (ODYSSEY OPTIONS II)

PHASE3

To evaluate the reduction of low-density lipoprotein cholesterol (LDL-C) by...

Status

Completed

Location

Multiple Locations

Start Date

2012-11-30

Trial ID

NCT01730053

Treatments Being Tested

Alirocumab Rosuvastatin Ezetimibe Placebo

Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)

PHASE3

Primary Objectives: * To demonstrate the superiority of alirocumab in comp...

Status

Completed

Location

Investigational Site Number 840020

Start Date

2015-10-23

Trial ID

NCT02585778

Treatments Being Tested

Alirocumab Placebo Lipid-Modifying Therapy (LMT)Antihyperglycemic Drug

An 8-Week Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia

PHASE2

Primary Objective: To evaluate the effect of alirocumab on low-density lip...

Status

Completed

Location

Investigational Site Number 8400002

Start Date

2016-09-15

Trial ID

NCT02890992

Treatments Being Tested

alirocumab SAR236553 (REGN727)statins ezetimibe cholestyramine fenofibrate omega-3 fatty acids nicotinic acid

Long-term Safety and Tolerability of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term)

PHASE3

Alirocumab (SAR236553/REGN727) is a fully human monoclonal antibody that bi...

Status

Completed

Location

Investigational Site Number 840159

Start Date

2012-01

Trial ID

NCT01507831

Treatments Being Tested

Placebo (for alirocumab)Alirocumab Lipid-Modifying Therapy (LMT)

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy

PHASE3

Alirocumab (SAR236553/REGN727) is a fully human monoclonal antibody that bi...

Status

Completed

Location

Investigational Site Number 840417

Start Date

2012-07

Trial ID

NCT01623115

Treatments Being Tested

Alirocumab Placebo (for alirocumab)Lipid Modifying Therapy (LMT)

Previous Next